Q1 FY27 results: Revenue falls 12% YoY to Rs 20.7 cr

Revenue DeclineResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-7.2%Reaction day

₹28.58

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%-7.1% vs market

Pharmaceuticals peers, median of 164sector+0.1%-7.3% vs sector

On the reaction day the stock moved 7.1 pts less than Nifty Microcap 250 and 7.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-7.2-0.2-7.1+0.1-7.3

Next day

-4.8+0.2-5.0-0.4-4.4

+1.2+0.4+0.8+0.1+1.1

+3.2+0.4+2.8-0.5+3.7

-2.0+0.6-2.6-0.9-1.1

-1.4+0.9-2.4-0.5-1.0

-5.5+0.9-6.4-1.0-4.6

15d

+3.9+0.9+3.0-0.8+4.7

-4.7+2.3-7.0+1.1-5.8

+20.6-1.1+21.8-3.1+23.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kimia Biosciences declared Q1 FY27 (Apr-Jun 2026) unaudited standalone results. Revenue from operations fell to Rs 20.7 cr from Rs 23.6 cr in Q1 FY26, a YoY decline of around 12%. Sequentially, revenue dropped 24% from Rs 27.2 cr in Q4 FY26. Total income for the quarter was Rs 20.8 cr. EPS stood at Rs 0.08 compared to Rs 0.13 in Q1 FY26 and Rs 1.64 for full year FY26. The statutory auditor issued an unqualified review report with no qualifications. The company operates in a single Pharmaceuticals segment.

Likely market impact

Revenue decline YoY and QoQ may weigh on near-term sentiment, though clean audit review provides some comfort.